Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: Results from four randomised, double-blind studies

npj Primary Care Respiratory Medicine

Volumn 27, Issue 1, 2017, Pages

  Ferguson, Gary ^a   Karpel, Jill ^b   Bennett, Nathan ^c   Clerisme Beaty, Emmanuelle ^c   Grönke, Lars ^d   Voß, Florian ^d   Buhl, Roland ^e  

^a Pulmonary Research Institute of Southeast Michigan   (United States)

^b North Shore Medical Arts LLP   (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; OLODATEROL; OLODATEROL PLUS TIOTROPIUM BROMIDE; SALBUTAMOL; THEOPHYLLINE; TIOTROPIUM BROMIDE; BENZOXAZINE DERIVATIVE; BRONCHODILATING AGENT;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DYSPNEA; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MONOTHERAPY; MULTICENTER STUDY (TOPIC); PATIENT-REPORTED OUTCOME; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; SOFT MIST INHALER; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYMPTOM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; DOUBLE BLIND PROCEDURE; FORCED EXPIRATORY VOLUME; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VITAL CAPACITY;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGED; BENZOXAZINES; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PATIENT REPORTED OUTCOME MEASURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TIOTROPIUM BROMIDE; VITAL CAPACITY;

EID: 85013319117     PISSN: None     EISSN: 20551010     Source Type: Journal    
DOI: 10.1038/s41533-016-0002-x     Document Type: Article

References (33)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2016. Last accessed on 27 April 2016. Available at http://www. goldcopd. org/.
2. Cavaillès, A., Brinchault-Rabin, G., Dixmier, A., Goupil, F., Gut-Gobert, C., Marchand-Adam, S., et al. Comorbidities of COPD. Eur. Respir. Rev. 22, 454-475 (2013).
3. Wu, M., Zhao, Q., Chen, Y., Fu, C., Xu, B. Quality of life and its association with direct medical costs for COPD in urban China. Health Qual. Life Outcomes 13, 57 (2015).
4. Wacker, M. E., Hunger, M., Karrasch, S., Heinrich, J., Peters, A., Schulz, H., et al. Health-related quality of life and chronic obstructive pulmonary disease in early stages-longitudinal results from the population-based KORA cohort in a working age population. BMC Pulm. Med. 14, 134 (2014).
5. Osman, L. M., Godden, D. J., Friend, J. A. R., Legge, J. S., Douglas, J. G. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 52, 67-71 (1997).
6. Seemungal, T. A. R., Donaldson, G. C., Paul, E. A., Bestall, J. C., Jeffries, D. J., Wedzicha, J. A. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 157, 1418-1422 (1998).
7. Casaburi, R., Mahler, D. A., Jones, P. W., Wanner, A., San Pedro, G., ZuWallack, R. L., et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 19, 217-224 (2002).
8. O'Donnell, D. E., Flüge, T., Gerken, F., Hamilton, A., Webb, K., Aguilaniu, B., et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur. Respir. J. 23, 832-840 (2004).
9. Maltais, F., Hamilton, A., Marciniuk, D., Hernandez, P., Sciurba, F. C., Richter, K., et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 128, 1168-1178 (2005).
10. Tashkin, D. P., Celli, B., Senn, S., Burkhart, D., Kesten, S., Menjoge, S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 359, 1543-1554 (2008).
11. Bateman, E. D., Tashkin, D., Siafakas, N., Dahl, R., Towse, L., Massey, D., et al. A one-year trial of tiotropium Respimat® plus usual therapy in COPD patients. Respir. Med. 104, 1460-1472 (2010).
12. Yohannes, A. M., Willgoss, T. G., Vestbo, J. Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes. Respir. Care 56, 477-487 (2011).
13. Vogelmeier, C., Hederer, B., Glaab, T., Schmidt, H., Rutten-van Mölken, M. P. M. H., Beeh, K. M., et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N. Engl. J. Med. 364, 1093-1103 (2011).
14. Ferguson, G. T., Feldman, G. J., Hofbauer, P., Hamilton, A., Allen, L., Korducki, L., et al. Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int. J. Chron. Obstruct. Pulmon. Dis. 9, 629-645 (2014).
15. Koch, A., Pizzichini, E., Hamilton, A., Hart, L., Korducki, L., De Salvo, M. C., et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int. J. Chron. Obstruct. Pulmon. Dis 9, 697-714 (2014).
16. Feldman, G. J., Bernstein, J. A., Hamilton, A., Nivens, M. C., Korducki, L., LaForce, C. The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2-4 COPD: results from two 6-week crossover studies. Springerplus 3, 419 (2014).
17. Lange, P., Aumann, J.-L., Hamilton, A., Tetzlaff, K., Ting, N., Derom, E. The 24 hour lung function time profile of olodaterol once daily versus placebo and tiotropium in patients with moderate to very severe chronic obstructive pulmonary disease. J. Pulm. Respir. Med. 4, 196 (2014).
18. Buhl, R., Maltais, F., Abrahams, R., Bjermer, L., Derom, E., Ferguson, G., et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur. Respir. J. 45, 969-979 (2015).
19. Singh, D., Ferguson, G. T., Bolitschek, J., Grönke, L., Hallmann, C., Bennett, N., et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir. Med. 109, 1312-1319 (2015).
20. Beeh, K.-M., Westerman, J., Kirsten, A.-M., Hébert, J., Grönke, L., Hamilton, A., et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 32, 53-59 (2015).
21. Beeh, K.-M., Derom, E., Echave-Sustaeta, J., Grönke, L., Hamilton, A., Zhai, D., et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study). Int. J. Chron. Obstruct. Pulmon. Dis. 11, 193-205 (2016).
22. Bateman, E. D., Ferguson, G. T., Barnes, N., Gallagher, N., Green, Y., Henley, M., et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur. Respir. J. 42, 1484-1494 (2013).
23. Donohue, J. F., Maleki-Yazdi, M. R., Kilbride, S., Mehta, R., Kalberg, C., Church, A. Efficacy and safety of once-daily umeclidinium/vilanterol 62. 5/25 mcg in COPD. Respir. Med. 107, 1538-1546 (2013).
24. Maleki-Yazdi, M. R., Kaelin, T., Richard, N., Zvarich, M., Church, A. Efficacy and safety of umeclidinium/vilanterol 62. 5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir. Med. 108, 1752-1760 (2014).
25. European Medicines Agency. Anoro summary of product characteristics. Updated June 2014. Last accessed on 9 March 2016. Available at http://www. ema. europa. eu/ema/index. jspcurl=pages/medicines/human/medicines/002751/human-med-001754. jsp&mid=WC0b01ac058001d124.
26. Decramer, M., Anzueto, A., Kerwin, E., Kaelin, T., Richard, N., Crater, G., et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir. Med. 2, 472-486 (2014).
27. Witek, T. J. Jr., Mahler, D. A. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur. Respir. J. 21, 267-272 (2003).
28. Perez, T., Burgel, P. R., Paillasseur, J.-L., Caillaud, D., Desleé, G., Chanez, P., et al. Modified Medical Research Council scale vs Baseline Dyspnea Index to evaluate dyspnea in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 10, 1663-1672 (2015).
29. Agusti, A., Hedner, J., Marin, J. M., Barbé, F., Cazzola, M., Rennard, S. Night-time symptoms: a forgotten dimension of COPD. Eur. Respir. Rev. 20, 183-194 (2011).
30. van der Molen, T., Cazzola, M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim. Care Respir. J. 21, 101-108 (2012).
31. Mahler, D. A. Mechanisms and measurement of dyspnea in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 3, 234-238 (2006).
32. Mahler, D. A., Weinberg, D. H., Wells, C. K., Feinstein, A. R. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 85, 751-758 (1984).
33. Jones, P. W. Estimation and application of the minimum clinically important difference in COPD. Lancet Respir. Med. 2, 167-169 (2014).